Amplification and overexpression of MDM2 in primary (de novo) glioblastomas

被引:136
作者
Biernat, W
Kleihues, P
Yonekawa, Y
Ohgaki, H
机构
[1] INT AGCY RES CANC,UNIT MOL PATHOL,F-69372 LYON 08,FRANCE
[2] UNIV ZURICH HOSP,DEPT NEUROSURG,CH-8091 ZURICH,SWITZERLAND
关键词
amplification; MDM2; overexpression; primary glioblastoma; secondary glioblastoma;
D O I
10.1097/00005072-199702000-00009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glioblastoma multiforme (WHO Grade IV), the most malignant neoplasm of the human nervous system, develops rapidly de novo (primary glioblastoma) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastoma). We recently reported that mutations of the p53 gene are present in more than two-thirds of secondary glioblastomas but rarely occur in primary glioblastomas, suggesting the presence of different genetic pathways (Watanabe et al, Brain Pathol 1996;6:217-24). In the present study, primary and secondary glioblastomas were screened by immunohistochemistry for MDM2 overexpression and by differential PCR for gene amplification. Tumor cells immunoreactive to MDM2 were found in 15 of 29 primary glioblastomas (52%), but in only 3 of 27 secondary glioblastomas (11%; P=0.0015). MDM2 amplification occurred in 2 primary (7%) glioblastomas but in none of the secondary glioblastomas. Only one out of 15 primary glioblastomas overexpressing MDM2 contained a p53 mutation. These results suggest that MDM2 overexpression with or without gene amplification constitutes a molecular mechanism of escape From p53-regulated growth control, operative in the evolution of primary glioblastomas that typically lack p53 mutations.
引用
收藏
页码:180 / 185
页数:6
相关论文
共 41 条
  • [1] MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY
    BARAK, Y
    JUVEN, T
    HAFFNER, R
    OREN, M
    [J]. EMBO JOURNAL, 1993, 12 (02) : 461 - 468
  • [2] ENHANCED BINDING OF A 95-KDA PROTEIN TO P53 IN CELLS UNDERGOING P53-MEDIATED GROWTH ARREST
    BARAK, Y
    OREN, M
    [J]. EMBO JOURNAL, 1992, 11 (06) : 2115 - 2121
  • [3] REGULATION OF MDM2 EXPRESSION BY P53 - ALTERNATIVE PROMOTERS PRODUCE TRANSCRIPTS WITH NONIDENTICAL TRANSLATION POTENTIAL
    BARAK, Y
    GOTTLIEB, E
    JUVENGERSHON, T
    OREN, M
    [J]. GENES & DEVELOPMENT, 1994, 8 (15) : 1739 - 1749
  • [4] BRUSTLE O, 1992, CANCER, V69, P2385, DOI 10.1002/1097-0142(19920501)69:9<2385::AID-CNCR2820690929>3.0.CO
  • [5] 2-3
  • [6] CARDONCARDO C, 1994, CANCER RES, V54, P794
  • [7] INTERACTIONS BETWEEN P53 AND MDM2 IN A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY
    CHEN, CY
    OLINER, JD
    ZHAN, QM
    FORNACE, AJ
    VOGELSTEIN, B
    KASTAN, MB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (07) : 2684 - 2688
  • [8] THE TUMOR-SUPPRESSOR P53
    DONEHOWER, LA
    BRADLEY, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (02) : 181 - 205
  • [9] ONCOGENE AMPLIFICATION IN UROTHELIAL CANCERS WITH P53 GENE MUTATION OR MDM2 AMPLIFICATION
    HABUCHI, T
    KINOSHITA, H
    YAMADA, H
    KAKEHI, Y
    OGAWA, O
    WU, WJ
    TAKAHASHI, R
    SUGIYAMA, T
    YOSHIDA, O
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (17) : 1331 - 1335
  • [10] BIOCHEMICAL-PROPERTIES AND BIOLOGICAL EFFECTS OF P53
    HAFFNER, R
    OREN, M
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 1995, 5 (01) : 84 - 90